Stock analysts at Deutsche Bank began coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued on Tuesday, The Fly reports. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other brokerages have also commented on REGN. Leerink Swann restated a “positive” rating and set a $552.00 price target (down from $580.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 15th. BMO Capital Markets set a $444.00 target price on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, November 27th. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $480.00 to $380.00 in a research report on Friday, December 1st. Robert W. Baird raised Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research report on Friday, November 3rd. Finally, Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Two investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $467.84.

Shares of Regeneron Pharmaceuticals (NASDAQ REGN) traded up $0.40 during trading hours on Tuesday, reaching $381.72. The company’s stock had a trading volume of 456,416 shares, compared to its average volume of 905,445. The firm has a market capitalization of $40,910.63, a price-to-earnings ratio of 32.97, a PEG ratio of 1.50 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. Regeneron Pharmaceuticals has a 12 month low of $340.09 and a 12 month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm’s revenue was up 23.0% on a year-over-year basis. During the same period in the prior year, the firm posted $3.13 earnings per share. research analysts predict that Regeneron Pharmaceuticals will post 13.55 EPS for the current year.

In related news, Director Michael S. Brown sold 1,500 shares of the stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Charles A. Baker sold 2,000 shares of the stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. Corporate insiders own 10.80% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Sequoia Financial Advisors LLC raised its stake in Regeneron Pharmaceuticals by 1.7% during the second quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 12 shares in the last quarter. Capital Planning Advisors LLC raised its stake in Regeneron Pharmaceuticals by 2.1% during the second quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 12 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Regeneron Pharmaceuticals by 0.4% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,661 shares of the biopharmaceutical company’s stock valued at $2,780,000 after buying an additional 20 shares in the last quarter. National Asset Management Inc. raised its stake in Regeneron Pharmaceuticals by 3.1% during the second quarter. National Asset Management Inc. now owns 856 shares of the biopharmaceutical company’s stock valued at $421,000 after buying an additional 26 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. raised its stake in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 28 shares in the last quarter. 66.67% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/12/regeneron-pharmaceuticals-regn-coverage-initiated-at-deutsche-bank.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.